Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
arcticnovartis

  • Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAddition
  • Consistent secondary endpoint results, including PSA progression and time to mCRPC, and safety profile reinforce broad clinical applicability
  • Promising Phase 1 data for Novartis actinium-based RLT also presented, supporting two Phase 3 trials and reinforcing Novartis global RLT leadership
/by

Pushing the prostate cancer treatment frontier: Radioligand therapy and beyond

Pushing the prostate cancer treatment frontier: Radioligand therapy and beyond
halesmi2

/by

Pushing the prostate cancer treatment frontier: Radioligand therapy and beyond

Pushing the prostate cancer treatment frontier: Radioligand therapy and beyond
halesmi2

/by

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
arcticnovartis

  • Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented
  • 124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be featured
  • New insights into disease characteristics in IgAN and C3G inform future research and treatment approaches
/by

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
arcticnovartis

  • Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented
  • 124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be featured
  • New insights into disease characteristics in IgAN and C3G inform future research and treatment approaches
/by

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
arcticnovartis

  • Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer
  • Kisqali® NATALEE oral presentation to report prognostic and predictive impact of gene expression from largest biomarker CDK4/6i trial dataset
  • Scemblix® ASC4FIRST oral presentation to feature longer-term 144-week efficacy, safety and tolerability data in first-line Ph+ CML-CP
/by

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
arcticnovartis

  • More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC alone
  • Deep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12, 24 and 48 weeks
  • sNDA filed in US, China and Japan; decisions expected H2 2026
/by

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
arcticnovartis

  • US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast–to–coast RLT manufacturing network – the largest in the US
  • Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
  • Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing
/by

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
arcticnovartis

  • US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast–to–coast RLT manufacturing network – the largest in the US
  • Expanded infrastructure brings highly personalized cancer therapies closer to patients across the southern US
  • Denton groundbreaking is latest milestone in Novartis’ $23 billion investment in US research and manufacturing
/by